Leukemia drug cocktail aims to boost remission in High-Risk patients
NCT ID NCT03455504
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether adding the targeted drug venetoclax to standard chemotherapy helps more adults with acute myeloid leukemia (AML) achieve remission. It enrolls people aged 18 to 65 with intermediate- or high-risk AML who have not yet been treated. The main goal is to see how many patients have no signs of leukemia after one or two rounds of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax added to standard chemotherapy (fludarabine, cytarabine, idarubicin)
- What this could lead to
- If successful, this combination could improve remission rates for people with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a mid-stage trial, so the added benefit of venetoclax is not yet proven. Side effects from the stronger drug combination may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Careggi - Ematologia
Florence, Italy
-
Aou "San Giovanni Di Dio E Ruggi D'Aragona" - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche
Salerno, Italy
-
Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia - Università Degli Studi Di Torino
Torino, Italy
-
Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia
Bologna, Italy
-
Aou Senese - Uoc Ematologia E Trapianti
Siena, Italy
-
Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia
Pagani, Italy
-
Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia
Vicenza, Italy
-
Dipartimento Oncologico - Ospedale S. Maria delle Croci
Ravenna, Italy
-
Dipartimento di Oncologia ed Ematologia S.C. -Città della Scienza di Torino San Giovanni Battista
Torino, Italy
-
Ematologia - ASST Papa Giovanni XXIII
Bergamo, Italy
-
Fondazione Irccs "Istituto Nazionale Tumori" - Milano - Sc Ematologia
Milan, Italy
-
Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia
Pavia, Italy
-
Irccs Aou San Martino - Genova - Uo Clinica Ematologica
Genova, Italy
-
Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia
Rozzano, Italy
-
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori IRST
Meldola, Italy
-
Ospedale Niguarda "Ca Granda" SC Ematologia
Milan, Italy
-
Spedali Civili - Azienda Ospedaliera U.O. Ematologia
Brescia, Italy
-
U.O. Ematologia e Trapianto di Midollo Ist. Scientifico Ospedale San Raffaele
Milan, Italy
-
U.O.C. Ematologia e CTMO Az Ospedaliero Universitaria
Parma, Italy
-
Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
Roma, Italy
-
Università degli Studi "Sapienza" Dip. Biotecnologie Cellulari ed Ematologia
Roma, Italy
-
Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
Catania, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?
- Could bone marrow from deceased donors cure blood cancers?
- Targeted drug aims to stop blood cancer return after transplant